Important note: Information in this article was accurate in August 2004. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 5, No. 7, August/September 2004
Simon Collins, HIV i-Base
Interaction data were presented again from the BI 1182.51 study using tipranavir with additional protease inhibitors in extensively PI-experienced patients. [1] Although management of treatment-experienced patients has often included multiple-PI and boosted-PI regimens, the negative interaction of tipranavir in reducing levels of saquinavir, amprenavir and lopinavir/r must be remembered.
HTB reported this data in full when it was presented at the pharmacology workshop earlier this year, and no new data was added to the analysis in Bangkok. [2]
Tipranavir is available in the UK on an expanded access programme.
References
| 1. | Walmsley S, Leith J, Katlama C et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51. Int Conf AIDS. 2004 Jul 11-16;15:Abstract No. WeOrB1236. |
| 1. | See HIV Treat Bull 2004 May 5(4);6 |
040810
IB040507-15
©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
